Glioblastoma (GBM) is a common and highly aggressive brain cancer. Currently, no treatment is curative, and its 5-year survival rate is less than 10%. Chimeric Antigen Receptor (CAR) T-cell therapy, which involves engineering a patient’s own T cells to mount a more effective antitumor response, is a promising immunotherapy approach to GBM treatment since activated T cells are able to not only cross the blood-brain barrier but also induce a potential antitumor response. CD70 and cytomegalovirus (CMV) pp65 are tumor-specific antigens found in GBMs that have been identified as promising targets for CAR T-cell therapy. Due to the heterogeneity of GBM, using only CD70-specific CAR T cells or pp65-specific CAR T cells individually is insufficient to fully control tumor progression and prevent relapse; however, recent studies on acute myeloid leukemia (AML) showed that a compound CAR (cCAR) T cell targeting two tumor-specific antigens can generate robust anti-tumor activity and consistent cytotoxicity to cells expressing one or both target antigens. We propose to develop dual target T cells that are able to target both pp65 and CD70 and to improve the cytotoxic activity of such T cells against GBM.